Novo Nordisk, a global healthcare company, announced that the European Commission has granted an extension of the indication for Fiasp (fast─acting insulin aspart), approving it for the treatment of diabetes in
Novo Nordisk, a global healthcare company, announced that the European Commission has granted an extension of the indication for Fiasp (fast─acting insulin aspart), approving it for the treatment of diabetes in
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
